These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19169606)

  • 1. [Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer].
    Fattoruso SI; Rossi S; Vici P; Di Filippo F; Botti C; Di Lauro L; Foggi P; Saracca E; Ferranti FR; Visca P; Lopez M
    Clin Ter; 2008; 159(6):443-7. PubMed ID: 19169606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel in the treatment of breast cancer: an update on recent studies.
    Nabholtz JM; Reese DM; Lindsay MA; Riva A
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):28-34. PubMed ID: 12170449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expanding role of epirubicin in the treatment of breast cancer.
    Glück S
    Cancer Control; 2002; 9(2 Suppl):16-27. PubMed ID: 11965227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial].
    Boér K; Láng I; Juhos E; Pintér T; Szántó J
    Magy Onkol; 2003; 47(2):141-8. PubMed ID: 12975660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.
    Trudeau M; Charbonneau F; Gelmon K; Laing K; Latreille J; Mackey J; McLeod D; Pritchard K; Provencher L; Verma S
    Lancet Oncol; 2005 Nov; 6(11):886-98. PubMed ID: 16257797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
    Guarneri V; Frassoldati A; Bruzzi P; D'Amico R; Belfiglio M; Molino A; Bertetto O; Cascinu S; Cognetti F; Di Leo A; Pronzato P; Crinó L; Agostara B; Conte P
    Clin Breast Cancer; 2008 Oct; 8(5):453-6. PubMed ID: 18952561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
    Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer.
    Zhang XH; Hao S; Gao B; Tian WG; Jiang Y; Zhang S; Guo LJ; Luo DL
    Oncotarget; 2016 Dec; 7(51):84533-84543. PubMed ID: 27811367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
    Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
    J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?
    Valero V; Hortobagyi GN
    J Clin Oncol; 2003 Mar; 21(6):959-62. PubMed ID: 12637456
    [No Abstract]   [Full Text] [Related]  

  • 14. A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.
    Di Leo A; Crown J; Nogaret JM; Duffy K; Bartholomeus S; Dolci S; Rowan S; O'Higgins N; Paesmans M; Larsimont D; Riva A; Piccart MJ
    Ann Oncol; 2000 Feb; 11(2):169-75. PubMed ID: 10761751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
    Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
    Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of taxanes in the adjuvant setting of node-negative breast cancers].
    Lagha A; Chraiet N; Labidi S; Krimi S; Ayadi M; Gligorov J; Boussen H
    Bull Cancer; 2013 May; 100(5):465-71. PubMed ID: 23613145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ongoing US cooperative group trials using taxanes in the adjuvant setting.
    Davidson NE
    Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S53-8. PubMed ID: 12435293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of taxanes in treatment of breast cancer].
    Gorbunova VA; Besova NS
    Vopr Onkol; 2004; 50(4):492-500. PubMed ID: 15605777
    [No Abstract]   [Full Text] [Related]  

  • 20. Docetaxel-anthracycline combinations in metastatic breast cancer.
    Nabholtz JM
    Breast Cancer Res Treat; 2003; 79 Suppl 1():S3-9. PubMed ID: 12868800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.